|
Physiomics PLC on Wednesday said it entered into a further contract with its existing client Cancer Research UK to conduct analyses of a blood cancer treatment.
The Oxford, England-based mathematical models consultancy, which aims to support the development of drug treatment regimens and personalised medicine solutions, said it was first contracted in 2019 to conduct pharmacokinetics analyses of clinical data arising from the Cancer Research UK-sponsored phase 1 and 2 clinical trial in Bicycle Therapeutics’ BT1718 treatment.
A follow-on project was announced today, in which Physiomics will be directly contracted by Cancer Research UK and will conduct pharmacodynamics analyses of the Aleta-001 clinical trial.
Aleta-001 is a Cancer Research UK-sponsored CAR-T cell engager candidate for the treatment of blood cancers. It is being developed by Aleta Biotherapeutics.
‘We are very pleased to be working on this second project with Cancer Research UK, the UK’s leading cancer research charity and look forward to developing our relationship further going forwards,’ said Physiomics Chief Executive Officer Jim Millen.
The project is expected to be completed during the first quarter of 2023.
Shares in Physiomics were down 7.6% to 4.30 pence each in London on Wednesday at midday.
By Greg Rosenvinge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
